NDLI: Radiolabelled Monoclonal Antibody Distribution in Human Tumor during Radioimmunotherapy (RIT)

Content Provider	IEEE Xplore Digital Library
Author	Lv, Yonggang Yang, Li Fu, Bingmei M. Cheung, Nai-Kong V.
Copyright Year	2010
Abstract	To optimize the delivery efficacy in RIT, a regional tissue distribution model and pharmacokinetics of radiolabelled mAbs in region solid tumor tissue were developed to quantify the time-dependent radioactivities on the free (CIA(t)) and bound (CIAR(t)) antibodies, the total amount of radioactivity per gram of solid tumor tissue (CIT(t)) in tumor tissue, and radioactivity on free antibodies in plasma (CIA-b(t)), under various conditions. The criteria for the optimal delivery in RIT are to maximize the area under the curve (AUC) of CIT(t), AUC(CIT(t)), and minimize the ratio activity in tumor to activity in plasma AUC(CIT)/AUC(CIA-b). Our results showed that: 1) The association and dissociation rate coefficients of antibodies to receptors have the same effects on optimal delivery under our clinical conditions of radioactive isotope half life ~8.5 days, clearance rate of antibody in plasma 17.35 ml/hr in human, and the tumor antigen concentration is 3.82×10^15 antigens/ml; 2) The change from 10^-8 M to 10^-9 M in the equilibrium dissociation constant has the most improvement in optimal delivery. In contrast, further change from 10^-9 M to 10^-10 M has only insignificant improvement.
Starting Page	1
Ending Page	3
File Size	299890
Page Count	3
File Format	PDF
ISBN	9781424447121
ISSN	21517622
DOI	10.1109/ICBBE.2010.5516434
Language	English
Publisher	Institute of Electrical and Electronics Engineers, Inc. (IEEE)
Publisher Date	2010-06-18
Publisher Place	China
Access Restriction	Subscribed
Rights Holder	Institute of Electrical and Electronics Engineers, Inc. (IEEE)
Subject Keyword	Microscopy Humans Plasmas Mathematical model Isotopes Tumors Cancer
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Radioimmunotherapy (RIT) in Brain Tumors.

Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel

Biodistribution of a radiolabelled monoclonal antibody

Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model.

Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using.

Cellular distribution of a monoclonal antibody in human tumours after i.v. administration (1981)

Strategies to enhance monoclonal antibody uptake and distribution in solid tumors

Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

Radiolabelled Monoclonal Antibody Distribution in Human Tumor during Radioimmunotherapy (RIT)

Similar Documents

Radioimmunotherapy (RIT) in Brain Tumors.

Radioimmunotherapy (RIT) Dose-Escalation Studies in Prostate Cancer Using Anti-PSMA Antibody 177Lu-J591: RIT Alone and RIT in Combination with Docetaxel

Biodistribution of a radiolabelled monoclonal antibody

Maximum tolerated dose and large tumor radioimmunotherapy studies of 64Cu-labeled monoclonal antibody 1A3 in a colon cancer model.

Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using.

Cellular distribution of a monoclonal antibody in human tumours after i.v. administration (1981)

Strategies to enhance monoclonal antibody uptake and distribution in solid tumors

Bismuth-213 radioimmunotherapy with C595 anti–MUC1 monoclonal antibody in an ovarian cancer ascites model

Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy

Radiolabelled Monoclonal Antibody Distribution in Human Tumor during Radioimmunotherapy (RIT)